Variable | AMAN (N = 43) | AMSAN (N = 28) | P-value | OR (95% CI) | |
---|---|---|---|---|---|
N (%) or Median (IQR) | N (%) or Median (IQR) | ||||
Age, years | 38 (25–52) | 38 (27.25–60.25) | 0.34 | ||
Sex (men) | 25/43 (58.1) | 15/28 (53.6) | 0.70 | ||
Time of antecedent event before symptom onset, days | 10 (7–14) | 10 (5–14) | 0.98 | ||
Time from symptom onset to presentation, days | 4 (2–7) | 7 (2–14) | 0.07 | ||
Clinical features at admission | |||||
Ophthalmoplegia | 1/43 (2.3) | 2/25 (8.0) | 0.55 | ||
Facial diplegia | 14/43 (32.6) | 13/25 (52.0) | 0.11 | ||
Oropharyngeal weakness | 9/43 (20.9) | 15/26 (57.7) | 0.002 | 5.2 (1.8–15) | |
Able to walk independently | 11/41 (26.8) | 5/27 (18.5) | 0.43 | ||
Antecedent infection | |||||
URTI | 7/38 (18.4) | 8/26 (30.8) | 0.25 | ||
Diarrhea | 22/38 (57.9) | 5/26 (19.2) | 0.002 | 5.8 (1.8–18.6) | |
Investigations | |||||
CSF Protein level, g/L | 0.5 (0.32–0.86) | 0.93 (0.59–2.4) | 0.036* | ||
CSF protein > 0.45 g/L | 20/36 (55.6) | 18/21 (85.7) | 0.02 | 4.8 (1.2–19.2) | |
Cell count > 5/µl | 3/36 (8.3) | 0/21 (0.0) | 0.30 | ||
Low FVC at admission | 7/26 (26.9) | 6/13 (46.2) | 0.29 | ||
Nerve root enhancement on MRI | 10/33 (30.3) | 6/19 (31.6) | 0.94 | ||
Hospital course | |||||
Repeated therapy | 10/41 (24.4) | 13/27 (48.1) | 0.043 | 2.9 (1.02–8.1) | |
ICU admission | 10/43 (23.3) | 20/28 (71.4) | < 0.001 | 8.3 (2.8–24.4) | |
Mechanical ventilation | 9/31 (29.0) | 17/27 (63.0) | 0.01 | 4.2 (1.4–12.5) | |
Tracheostomy | 5/29 (17.2) | 12/27 (44.4) | 0.03 | 3.8 (1.1–13.1) | |
Duration of ICU stay, days | 16 (5–29.25) | 33 (20–81) | 0.049 | ||
Duration of hospitalization, weeks | 2 (1–8.5) | 12 (3–44) | 0.001 | ||
Outcome | |||||
Able to walk independently at follow-up | 27/34 (79.4) | 11/19 (57.9) | 0.10 | ||
Duration of follow-up, months | 12.5 (4.6–20.8) | 8 (3.5–15.2) | 0.23 |